Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of the firm's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $51.09, for a total value of $638,625.00. Following the completion of the transaction, the insider directly owned 167,124 shares of the company's stock, valued at $8,538,365.16. The trade was a 6.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Timothy Rolph also recently made the following trade(s):
- On Wednesday, June 18th, Timothy Rolph sold 1,129 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.84, for a total value of $61,914.36.
- On Tuesday, June 10th, Timothy Rolph sold 2,358 shares of Akero Therapeutics stock. The stock was sold at an average price of $54.00, for a total value of $127,332.00.
- On Thursday, June 5th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $53.49, for a total value of $668,625.00.
- On Friday, June 6th, Timothy Rolph sold 25,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $55.04, for a total value of $1,376,000.00.
- On Tuesday, May 6th, Timothy Rolph sold 12,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $43.43, for a total value of $542,875.00.
- On Thursday, April 24th, Timothy Rolph sold 6,250 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.03, for a total value of $256,437.50.
Akero Therapeutics Trading Down 0.8%
Shares of AKRO traded down $0.43 during trading hours on Friday, hitting $51.57. The company had a trading volume of 618,863 shares, compared to its average volume of 1,054,935. The firm has a market cap of $4.11 billion, a P/E ratio of -26.45 and a beta of -0.15. The stock's 50 day moving average price is $49.59 and its 200 day moving average price is $43.60. The company has a quick ratio of 16.80, a current ratio of 16.80 and a debt-to-equity ratio of 0.03. Akero Therapeutics, Inc. has a 52-week low of $21.34 and a 52-week high of $58.40.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $1.91. On average, research analysts predict that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.
Hedge Funds Weigh In On Akero Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the company. Northwest & Ethical Investments L.P. bought a new position in Akero Therapeutics in the 1st quarter worth $32,000. GF Fund Management CO. LTD. purchased a new position in Akero Therapeutics in the fourth quarter worth about $41,000. Sterling Capital Management LLC boosted its position in shares of Akero Therapeutics by 764.3% during the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after buying an additional 1,582 shares during the period. PNC Financial Services Group Inc. boosted its position in shares of Akero Therapeutics by 30.8% during the first quarter. PNC Financial Services Group Inc. now owns 1,658 shares of the company's stock valued at $67,000 after buying an additional 390 shares during the period. Finally, Quarry LP bought a new stake in shares of Akero Therapeutics during the fourth quarter valued at approximately $83,000.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on AKRO shares. Bank of America lifted their price objective on Akero Therapeutics from $63.00 to $64.00 and gave the company a "buy" rating in a research note on Tuesday, May 27th. Citigroup dropped their price target on Akero Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Akero Therapeutics presently has an average rating of "Buy" and an average price target of $82.50.
Get Our Latest Analysis on AKRO
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Read More
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
